Effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on all-cause mortality, cardiovascular death, and cardiovascular events among peritoneal dialysis patients: A protocol for systematic review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
12
5
2020
Statut:
ppublish
Résumé
Based on the International Society for peritoneal dialysis (PD) recommendations, blockade of renin-angiotensin systems with an angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves residual kidney function in PD patients. However, the long-term effectiveness of ACEI/ARB use in PD patients has not been fully elucidated. We, therefore, intend to perform a systematic review and meta-analysis to summarize the effects of ACEI/ARB use on long-term mortality, cardiovascular outcomes, and adverse events among PD patients. This systematic review will include both randomized controlled trials and non-randomized studies in adult PD patients. We also plan to incorporate data from our cohort study in Thai PD population into this review. We will search PubMed, Medline, EMBASE, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature from inception to February 29, 2019, with no language restrictions. The process of study screening, selection, data extraction, risk of bias assessment, and grading the strength of evidence will be performed independently by a pair of reviewers. Any discrepancy will be resolved through a team discussion and/or consultation with the third reviewer. The pooled effects estimate and 95% confidence intervals will be estimated using DerSimonian-Laird random-effects models. Heterogeneity will be assessed by the Cochran Q test, I index and tau-squared statistics. The funnel plots along with the Begg and Egger test and trim and fill method will be performed to investigate any evidence of publication bias. Preplanned subgroup analyses and random-effects univariate meta-regressions will be performed to quantify the potential sources of heterogeneity based on studies- and patient-characteristics. This will be the first systematic review and meta-analysis to summarize the long-term effectiveness of renin-angiotensin system inhibitors in PD populations. In summary, this systematic review and meta-analysis will summarize the effectiveness of ACEI/ARB on long-term mortality, cardiovascular outcomes, and adverse events among adult PD patients by integrated all available evidences. Based on the existing published data, an ethical approval is not required. The findings will be disseminated through scientific meetings and publications in peer-reviewed journals.PROSPERO registration number: CRD42019129492.
Sections du résumé
BACKGROUND
BACKGROUND
Based on the International Society for peritoneal dialysis (PD) recommendations, blockade of renin-angiotensin systems with an angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves residual kidney function in PD patients. However, the long-term effectiveness of ACEI/ARB use in PD patients has not been fully elucidated. We, therefore, intend to perform a systematic review and meta-analysis to summarize the effects of ACEI/ARB use on long-term mortality, cardiovascular outcomes, and adverse events among PD patients.
METHODS
METHODS
This systematic review will include both randomized controlled trials and non-randomized studies in adult PD patients. We also plan to incorporate data from our cohort study in Thai PD population into this review. We will search PubMed, Medline, EMBASE, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature from inception to February 29, 2019, with no language restrictions. The process of study screening, selection, data extraction, risk of bias assessment, and grading the strength of evidence will be performed independently by a pair of reviewers. Any discrepancy will be resolved through a team discussion and/or consultation with the third reviewer. The pooled effects estimate and 95% confidence intervals will be estimated using DerSimonian-Laird random-effects models. Heterogeneity will be assessed by the Cochran Q test, I index and tau-squared statistics. The funnel plots along with the Begg and Egger test and trim and fill method will be performed to investigate any evidence of publication bias. Preplanned subgroup analyses and random-effects univariate meta-regressions will be performed to quantify the potential sources of heterogeneity based on studies- and patient-characteristics.
RESULTS
RESULTS
This will be the first systematic review and meta-analysis to summarize the long-term effectiveness of renin-angiotensin system inhibitors in PD populations.
CONCLUSION
CONCLUSIONS
In summary, this systematic review and meta-analysis will summarize the effectiveness of ACEI/ARB on long-term mortality, cardiovascular outcomes, and adverse events among adult PD patients by integrated all available evidences.
ETHICS AND DISSEMINATION
BACKGROUND
Based on the existing published data, an ethical approval is not required. The findings will be disseminated through scientific meetings and publications in peer-reviewed journals.PROSPERO registration number: CRD42019129492.
Identifiants
pubmed: 32332616
doi: 10.1097/MD.0000000000019767
pii: 00005792-202004240-00027
pmc: PMC7220652
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19767Références
Perit Dial Int. 2009 Sep-Oct;29(5):554-61
pubmed: 19776050
Nephrol Dial Transplant. 2009 Jan;24(1):272-7
pubmed: 18676349
Nat Rev Nephrol. 2017 Feb;13(2):90-103
pubmed: 28029154
Clinics (Sao Paulo). 2012 Aug;67(8):877-83
pubmed: 22948453
J Am Soc Nephrol. 2002 May;13(5):1307-1320
pubmed: 11961019
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482
pubmed: 29598869
Am J Kidney Dis. 2003 Jun;41(6):1293-302
pubmed: 12776283
BMC Nephrol. 2017 Jun 30;18(1):206
pubmed: 28666408
Am J Kidney Dis. 2004 Jun;43(6):1056-64
pubmed: 15168386
Perit Dial Int. 2007 Jul-Aug;27(4):446-53
pubmed: 17602154
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Cochrane Database Syst Rev. 2014 Jun 23;(6):CD009120
pubmed: 24953826
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
Perit Dial Int. 2015 Jul-Aug;35(4):379-87
pubmed: 26228782
Kidney Int. 2002 Aug;62(2):639-47
pubmed: 12110029
Nephrol Dial Transplant. 2009 Sep;24(9):2909-14
pubmed: 19225016
Clin Res Cardiol. 2008 Jul;97(7):418-31
pubmed: 18454336
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Sci Rep. 2019 Dec 20;9(1):19582
pubmed: 31862905
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Nat Rev Nephrol. 2010 Aug;6(8):451-60
pubmed: 20567248
Nephron Clin Pract. 2009;112(1):c31-40
pubmed: 19342867
Nephrology (Carlton). 2010 Feb;15(1):27-32
pubmed: 20377768
Curr Opin Nephrol Hypertens. 2019 Mar;28(2):171-177
pubmed: 30585852
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Am J Kidney Dis. 2016 May;67(5):728-41
pubmed: 26597926
Ther Apher Dial. 2013 Jun;17(3):298-304
pubmed: 23735145
Kidney Int. 2019 Sep;96(3):699-710
pubmed: 31200941
BMC Med Res Methodol. 2007 Jan 23;7:5
pubmed: 17244367
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Ann Intern Med. 2003 Jul 15;139(2):105-12
pubmed: 12859160
Adv Perit Dial. 2003;19:59-66
pubmed: 14763035
J Am Soc Nephrol. 2001 Oct;12(10):2158-2162
pubmed: 11562415
Clin Kidney J. 2018 Feb;11(1):108-122
pubmed: 29423210
Clin J Am Soc Nephrol. 2009 Oct;4(10):1620-8
pubmed: 19729428